litlas
ログインアカウント作成

Douglas B. Johnson

2013–2025 年に発表

267
論文数
49,243
被引用数
103
h 指数
249
i10 指数

被引用数

Douglas B. Johnson の年別被引用数1945 年: 被引用 1 件1974 年: 被引用 1 件2001 年: 被引用 1 件2003 年: 被引用 3 件2009 年: 被引用 2 件2010 年: 被引用 1 件2012 年: 被引用 4 件2013 年: 被引用 3 件2014 年: 被引用 46 件2015 年: 被引用 108 件2016 年: 被引用 193 件2017 年: 被引用 464 件2018 年: 被引用 620 件2019 年: 被引用 1,965 件2020 年: 被引用 3,046 件2021 年: 被引用 3,182 件2022 年: 被引用 2,951 件2023 年: 被引用 2,359 件2024 年: 被引用 4,166 件2025 年: 被引用 1,997 件2026 年: 被引用 42 件1946〜1973 年は被引用が無いため表示していません1975〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません2004〜2008 年は被引用が無いため表示していません2011 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,888 件、この内訳の 25.2%中国: 引用元論文 3,679 件、この内訳の 15.8%イタリア: 引用元論文 1,270 件、この内訳の 5.4%イギリス: 引用元論文 1,173 件、この内訳の 5%ドイツ: 引用元論文 1,140 件、この内訳の 4.9%フランス: 引用元論文 1,033 件、この内訳の 4.4%オーストラリア: 引用元論文 798 件、この内訳の 3.4%カナダ: 引用元論文 642 件、この内訳の 2.8%スペイン: 引用元論文 630 件、この内訳の 2.7%オランダ: 引用元論文 618 件、この内訳の 2.6%日本: 引用元論文 616 件、この内訳の 2.6%スイス: 引用元論文 554 件、この内訳の 2.4%
0%25.2%その他 22.8%

機関

分野

  • Medicine66.7%
  • Biochemistry, Genetics and Molecular Biology19.1%
  • Immunology and Microbiology9%
  • Engineering1.6%
  • Computer Science1.4%
  • Neuroscience0.4%
  • その他1.8%

トピック

  • Cancer Immunotherapy and Biomarkers15.6%
  • Immunotherapy and Immune Responses5.6%
  • CAR-T cell therapy research4.4%
  • Melanoma and MAPK Pathways3.5%
  • Immune Cell Function and Interaction2.8%
  • Cutaneous Melanoma Detection and Management2.6%
  • その他65.5%

共著者

全論文

検索で開く
  1. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

    著者: Daniel Wang, Joe‐Elie Salem, Justine V. Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E. Beckermann, Lisa Ha, W. Kimryn Rathmell, Kristin Kathleen Ancell, Justin M. Balko, Caitlin Bowman, Elizabeth J. Davis, David D. Chism, Leora Horn, Georgina V. Long, Matteo S. Carlino, Bénédicte Lebrun‐Vignes, Zeynep Eroglu, Jessica C. Hassel, Alexander M. Menzies, Jeffrey A. Sosman, Ryan J. Sullivan, Javid J. Moslehi, Douglas B. Johnson - JAMA Oncology 2018 被引用: 2,609

  2. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

    著者: Willy Hugo, Jesse M. Zaretsky, Lu ming Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu‐Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley H. Lomeli, Xiangju Kong, Mark C. Kelley, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Roger S. Lo - Cell 2016 被引用: 3,569

  3. Assessing the Accuracy and Reliability of AI-Generated Medical Responses: An Evaluation of the Chat-GPT Model

    著者: Douglas B. Johnson, Rachel Goodman, James R. Patrinely, Cosby A. Stone, Eli E. Zimmerman, Rebecca Donald, Sam S. Chang, Sean T. Berkowitz, Avni P. Finn, Eiman Jahangir, Elizabeth Scoville, Tyler Reese, Debra L. Friedman, Julie A. Bastarache, Yuri F. van der Heijden, J. J. Wright, Nick Carter, Matthew R. Alexander, Jennifer H. Choe, Cody A. Chastain, John A. Zic, Sara N. Horst, Isik Turker, Rajiv Agarwal, Evan C. Osmundson, Kamran Idrees, Colleen M. Kiernan, Chandrasekhar Padmanabhan, Christina E. Bailey, Cameron Schlegel, Lola B. Chambless, Mike Gibson, Travis Osterman, Lee Wheless - 2023 被引用: 599

  4. Immune-checkpoint inhibitors: long-term implications of toxicity

    著者: Douglas B. Johnson, Caroline A. Nebhan, Javid J. Moslehi, Justin M. Balko - Nature Reviews Clinical Oncology 2022 被引用: 913

  5. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

    著者: Francesca Finotello, Clemens Mayer, Christina Plattner, Gerhard Laschober, Dietmar Rieder, Hubert Hackl, Anne Krogsdam, Zuzana Loncová, Wilfried Posch, Doris Wilflingseder, Sieghart Sopper, Marieke E. Ijsselsteijn, Thomas P. Brouwer, Douglas B. Johnson, Yaomin Xu, Yu Wang, Melinda E. Sanders, Mónica V. Estrada, Paula I. González-Ericsson, Pornpimol Charoentong, Justin M. Balko, Noel F.C.C. de Miranda, Zlatko Trajanoski - Genome Medicine 2019 被引用: 1,681

  6. Fulminant Myocarditis with Combination Immune Checkpoint Blockade

    著者: Douglas B. Johnson, Justin M. Balko, Margaret Compton, Spyridon Chalkias, Joshua Gorham, Yaomin Xu, Mellissa Hicks, Igor Puzanov, Matthew R. Alexander, Tyler Bloomer, Jason R. Becker, David Slosky, Elizabeth J. Phillips, Mark A. Pilkinton, Laura Deeanne Craig-Owens, Nina Kola, Gregory E. Plautz, Daniel S. Reshef, Jonathan S. Deutsch, Raquel P. Deering, Benjamin A. Olenchock, Andrew H. Lichtman, Dan M. Roden, Christine E. Seidman, Igor J. Koralnik, Jonathan G. Seidman, Robert Hoffman, Janis M. Taube, Luis A. Díaz, Robert A. Anders, Jeffrey A. Sosman, Javid J. Moslehi - New England Journal of Medicine 2016 被引用: 2,276

  7. Accuracy and Reliability of Chatbot Responses to Physician Questions

    著者: Rachel Goodman, James R. Patrinely, Cosby A. Stone, Eli E. Zimmerman, Rebecca R. Donald, Sam S. Chang, Sean T. Berkowitz, Avni P. Finn, Eiman Jahangir, Elizabeth Scoville, Tyler Reese, Debra L. Friedman, Julie A. Bastarache, Yuri F. van der Heijden, J. J. Wright, Feifei Ye, Nick Carter, Matthew R. Alexander, Jennifer H. Choe, Cody A. Chastain, John A. Zic, Sara Horst, Isik Turker, Rajiv Agarwal, Evan C. Osmundson, Kamran Idrees, Colleen M. Kiernan, Chandrasekhar Padmanabhan, Christina E. Bailey, Cameron Schlegel, Lola B. Chambless, Michael K. Gibson, Travis Osterman, Lee Wheless, Douglas B. Johnson - JAMA Network Open 2023 被引用: 445

  8. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    著者: Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff - Journal for ImmunoTherapy of Cancer 2021 被引用: 826

  9. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

    著者: Satya Das, Douglas B. Johnson - Journal for ImmunoTherapy of Cancer 2019 被引用: 1,145

  10. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

    著者: Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, Bénédicte Lebrun‐Vignes, Lisa Bastarache, Alexandre Pariente, Aurélien Gobert, Jean‐Philippe Spano, Justin M. Balko, Marc P. Bonaca, Dan M. Roden, Douglas B. Johnson, Javid J. Moslehi - The Lancet Oncology 2018 被引用: 1,209

  11. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

    著者: Daniel Shae, Kyle W. Becker, Plamen P. Christov, Dong Soo Yun, Abigail K. R. Lytton‐Jean, Sema Sevimli, Manuel Ascano, Mark C. Kelley, Douglas B. Johnson, Justin M. Balko, John T. Wilson - Nature Nanotechnology 2019 被引用: 657

  12. T cells specific for α-myosin drive immunotherapy-related myocarditis

    著者: Margaret L. Axelrod, Wouter C. Meijers, Elles M. Screever, Juan Qin, Mary Grace Carroll, Xiaopeng Sun, Elie Tannous, Yueli Zhang, Ayaka Sugiura, Brandie C. Taylor, Ann Hanna, Shaoyi Zhang, Kaushik Amancherla, Warren Tai, J. J. Wright, Spencer C. Wei, Susan R. Opalenik, Abigail Toren, Jeffrey C. Rathmell, P. Brent Ferrell, Elizabeth J. Phillips, S. Mallal, Douglas B. Johnson, James P. Allison, Javid J. Moslehi, Justin M. Balko - Nature 2022 被引用: 321

  13. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

    著者: Javid J. Moslehi, Joe‐Elie Salem, Jeffrey A. Sosman, Bénédicte Lebrun‐Vignes, Douglas B. Johnson - The Lancet 2018 被引用: 914

  14. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

    著者: Steve Lu, Julie E. Stein, David L. Rimm, Daphne W. Wang, Michael A. Bell, Douglas B. Johnson, Jeffrey A. Sosman, Kurt A. Schalper, Robert A. Anders, Hao Wang, Clifford Hoyt, Drew M. Pardoll, Ludmila Danilova, Janis M. Taube - JAMA Oncology 2019 被引用: 622

  15. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    著者: Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen Van de Vijver, Mónica V. Estrada, Paula I. González-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes A. Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nucíforo, Laura Comerma, E. Aubrey Thompson, Sunil R. Lakhani, Seong-Rim Kim, Stuart J. Schnitt, Cécile Colpaert, Christos Sotiriou, Stefan Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frédérique Penault‐Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea L. Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin M. Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra A. O’Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix‐Triki, Marc J. van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph A. Sparano, David L. Rimm, Torsten O. Nielsen, Zuzana Kos, Stephen M. Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard‐Gallo, Hugo M. Horlings, Leena Gandhi, André Moreira, Fred R. Hirsch, Maria Vittoria Dieci, María Urbanowicz, Iva Brčić, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer M. Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan Juco, Carsten Denkert, Jorge S. Reis‐Filho, Sherene Loi, Stephen B. Fox - Advances in Anatomic Pathology 2017 被引用: 799

  16. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    著者: Douglas B. Johnson, Mónica V. Estrada, Roberto Salgado, Violeta Sánchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko - Nature Communications 2016 被引用: 572

  17. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer

    著者: Margaret L. Axelrod, Rebecca S. Cook, Douglas B. Johnson, Justin M. Balko - Clinical Cancer Research 2018 被引用: 496

  18. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

    著者: Ari M. Vanderwalde, Shay Bellasea, Kari Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances A. Collichio, Jeffrey A. Sosman, Alexandra P. Ikeguchi, Adrienne I. Victor, Thach‐Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu‐Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu, Antoni Ribas - Nature Medicine 2023 被引用: 167

  19. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    著者: Catherine S. Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodríguez, Petra Ross‐Macdonald, Megan Wind‐Rotolo, Ameya S. Champhekar, Egmidio Medina, Davis Y. Torrejon, Daniel Sanghoon Shin, Phuong Tran, Yeon Joo Kim, Cristina Puig-Saus, Katie M. Campbell, Agustin Vega-Crespo, Michael J. Quist, Christophe Martignier, Jason J. Luke, Jedd D. Wolchok, Douglas B. Johnson, Bartosz Chmielowski, F. Stephen Hodi, Shailender Bhatia, William Sharfman, Walter J. Urba, Craig L. Slingluff, Adi Diab, John B.A.G. Haanen, Salvador Martín‐Algarra, Drew M. Pardoll, Valsamo Anagnostou, Suzanne L. Topalian, Victor E. Velculescu, Daniel E. Speiser, Anusha Kalbasi, Antoni Ribas - Cancer Cell 2020 被引用: 383

  20. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    著者: Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, Carmen Mak, Daniel Wang, Rajat R Rai, John Park, Lauren E. Haydu, Christine N. Spencer, Matthew Wongchenko, Stephen Lane, Dung-Yang Lee, Mathilde Kaper, Meredith McKean, Kathryn E. Beckermann, Samuel M. Rubinstein, Isabelle Rooney, Luna Musib, Nageshwar Budha, Jessie J. Hsu, Theodore S. Nowicki, Alexandre Avila, T Haas, Mäneka Puligandla, Sandra Lee, Shenying Fang, Jennifer A. Wargo, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, Paul B. Chapman, Jeffrey A. Sosman, Dirk Schadendorf, Jean‐Jacques Grob, Keith T. Flaherty, Dana Walker, Yibing Yan, Edward McKenna, Jeffrey J. Legos, Matteo S. Carlino, Antoni Ribas, John M. Kirkwood, Georgina V. Long, Douglas B. Johnson, Alexander M. Menzies, Michael A. Davies - The Lancet Oncology 2018 被引用: 658

  21. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

    著者: Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod, Nana-Ama A.S. Anang, Elles M. Screever, Elizabeth C. Wescott, Douglas B. Johnson, Elizabeth M. Whitley, Lorenz Lehmann, Pierre‐Yves Courand, James J. Mancuso, Lauren E. Himmel, Bénédicte Lebrun-Vignes, Matthew J. Wleklinski, Björn C. Knollmann, Jayashree Srinivasan, Yu Li, Oluwatomisin T. Atolagbe, Xiayu Rao, Yang Zhao, Jing Wang, Lauren I. R. Ehrlich, Padmanee Sharma, Joe‐Elie Salem, Justin M. Balko, Javid J. Moslehi, James P. Allison - Cancer Discovery 2020 被引用: 272

  22. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

    著者: Balamayoora Theivanthiran, Kathy S. Evans, Nicholas C. DeVito, Michael P. Plebanek, Michael Sturdivant, Luke P. Wachsmuth, April K.S. Salama, Yubin Kang, David S. Hsu, Justin M. Balko, Douglas B. Johnson, Mark D. Starr, Andrew B. Nixon, Alisha Holtzhausen, Brent A. Hanks - Journal of Clinical Investigation 2020 被引用: 250

  23. Cardiovascular toxicities associated with immune checkpoint inhibitors

    著者: Jiun‐Ruey Hu, Roberta Florido, Evan J. Lipson, Jarushka Naidoo, Reza Ardehali, Carlo G. Tocchetti, Alexander R. Lyon, Robert F. Padera, Douglas B. Johnson, Javid J. Moslehi - Cardiovascular Research 2019 被引用: 506

  24. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

    著者: Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Omid Hamid, Josep M. Piulats, Matthew J. Rioth, Douglas B. Johnson, Jason J. Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Howard Goodall, Koustubh Ranade, Chris Holland, Shaad E. Abdullah, Joseph J. Sacco, Takami Sato - Nature Medicine 2022 被引用: 152